VTRS

Viatris Inc. Common Stock

$16.26 +0.93%

Recent alerts on VTRS

All signals →

News Theravance Sales Jump 83 Percent

News Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

News Viatris Misses Estimates, Cash Flow Up

News Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?

News JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

News Why Viatris Stock Is Jumping Today

News Here's Why You May Invest in Theravance (TBPH) Stock Now

News TrumpRx set to expand into generic medicines with Mark Cuban

News Large-cap stocks trading at discounted earnings multiples

News Most healthcare companies report higher Y/Y EPS in strong earnings week

News HHS officials considered banning SSRI antidepressants - report

News Viatris signals 2026 cash deployment of more than $2.5B while expecting Greater China mid- to high-single-digit growth

News Viatris rises as Q1 beat indicates growth momentum

News Viatris Non-GAAP EPS of $0.59 beats by $0.09, revenue of $3.51B beats by $150M

SEC filing VTRS Announces CEO NAME_1 Resignation Effective Immediately, Appoints NAME_2 as New CEO, 2024 Revenue $1.2B, EPS $0.45, 15% YoY Growth

News Stock index futures mixed as focus remains on U.S.-Iran developments

News Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

News Notable healthcare headlines for the week: J&J, Abbott and Organon in focus

News Quant check on David Einhorn's Greenlight Capital holdings post Q1

Insider trade Sale by Paul Campbell (Chief Accounting Officer and Corporate Controller)

News Catalyst Watch: Nvidia's GTC Conference, FOMC meeting, Okta event, and triple-witching day

News FDA plans to relax testing rules to encourage biosimilar drugs: report

News Theravance drops rare disease drug after late-stage trial setback

News Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus

News Glenview Capital's top Q4 moves include closing out PYPL, PINS stakes, boosting LION

Get push alerts for VTRS

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS